Injectable Cytotoxic Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Alkylating Drugs, Cytotoxic Antibodies, Antimetabolites, Plant Alkaloids, and Others), By Application (Oncology, Rheumatoid Arthritis, Multiple Sclerosis, and Others) By End-user (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Forecast, 2020-2027

The global injectable cytotoxic drugs market size was USD 15.81 billion in 2019. The global impact of COVID-19 has been unprecedented and staggering, with injectable cytotoxic drugs witnessing a positive demand shock across all regions amid the pandemic. Based on our analysis, the global market will exhibit a moderate growth of 8.5% in 2020. The market is projected to grow from USD 17.16 billion in 2020 to USD 29.60 billion in 2027 at a CAGR of 8.1% between 2020-2027. The fall in CAGR is attributable to this market’s demand and growth, returning to pre-pandemic levels once the pandemic is over.

Cytotoxic drugs are one of the vital drug classes used to treat prevalent diseases such as oncology disorders. These drugs are known for their cellular degeneration property that help to eradicate cancerous cells. Cytotoxic injectable medicines are prescribed as the first line of treatment for various types of cancer. The majority of the injectable cytotoxic drugs that are off-patent are available as generics in the global market. Cytotoxic drugs, also known as chemotherapy, are identified for their severe side effects such as bone marrow depression, follicle toxicity, and anemia. The increasing prevalence of cancer and high dependency on cytotoxic drugs for its treatment are predominant factors augmenting the growth of the market in the coming years. For instance, as per the American Cancer Society report, the majority of oncology disorders such as bladder, breast, testicular, uterus, etc. require chemotherapy from stage 2 itself.

COVID-19 Pandemic to Increase Demand for Cytotoxic Drugs  

The outbreak of COVID-19 has had a positive impact on the injectable cytotoxic drugs market globally. Certain market segments have witnessed a growth in demand for drugs with respect to the COVID-19 emergency. The pharmaceutical companies involved in this market have significantly improved their supply chain management, enhanced their R&D, and invested more in production and quality control. According to the quarterly reports of 2020 of Roche, their global supply chain of medicines and tests remain intact. Their pharmaceutical division sales increased by 7% as compared to the prior year. This growth was led by oncology drugs such as Tecentriq and Perjeta.

LATEST TRENDS

Request a Free sample to learn more about this report.

Strategic Collaborations among Industry Players is a Vital Trend

The Healthcare landscape has significantly changed owing to the collaborative approach between the non-traditional key players and the existing traditional players to provide a more customer-centric experience. Partnerships between the key players operating in the cytotoxic drugs market and pharmacy distributors have improved the healthcare supply chain’s productivity and are one of the key market trends. In November 2019, Bristol-Myers Squibb Company announced that it had completed Celgene’s acquisition, leading to the creation of a strong biopharmaceutical entity, due to the companies’ strong complementary portfolios of oncology, immunology, inflammation, and cardiovascular disease.

DRIVING FACTORS

High Dependency on Cytotoxic Drugs for Treatment of Disease Indication to Propel Market Growth

Cancer is a devastating disease, and due to disease heterogeneity, standard treatments such as chemotherapy or radiation are effective and highly adopted among the population. Additionally, cytotoxic drugs are predominantly used as the first line of treatment for a newly diagnosed cancer patient. The upcoming therapies, such as targeted therapy and immunotherapy, are currently only approved to treat specific cancer types. Additionally, most targeted and immunotherapy drugs are prescribed in combination with cytotoxic/ chemotherapy drugs. Cytotoxic drugs are also defined in patients with aggravated forms of multiple sclerosis.

Combined with this, there are a significant number of pipeline molecules under development that are indicated to be prescribed along with cytotoxic drugs. For instance, EMD Serono Research & Development Institute, Inc, in collaboration with Merck KGaA, is developing M4344. The molecule is in Phase 1 clinical trial combined with Carboplatin for the treatment of advanced solid tumors.

Surge in the Cancer and Rheumatoid Arthritis to Boost the Market Growth

Worldwide, cancer prevalence has increased tremendously to make it the second leading cause of death after cardiovascular disease. Environmental factors such as tobacco smoking, urbanization, and its associated pollution, and changing diet patterns are considered responsible for this phenomenon. For instance, according to the World Health Organization (WHO), cancer is a growing burden. The number of new cancer cases is expected to rise from 18.1 million in 2018 to 29.4 million by 2040.

Globally there is also a surge in the prevalence of rheumatoid arthritis and multiple sclerosis. This rise is estimated to increase the adoption of cytotoxic drugs in the treatment of the disease. According to the Center for Disease Control and Prevention, around 41 individuals out of 100,000 are affected with rheumatoid arthritis each year in the U.S.

RESTRAINING FACTORS

Advent of Alternate Therapies to Treat Cancer Could Restrain the Market

The upcoming novel therapies focused on immunotherapy and targeted therapy are highly efficacious and also exhibit lower side effects than cytotoxic drugs. These factors are likely to inhibit the growth of the injectable cytotoxic drugs market in the forthcoming years. The inherent variability of cancer contributes to the growing field of precision and personalized medicine (PPM). PPM cancer treatments have been proven to result in immense patient benefits, and thus various pharmaceutical companies are investing in this space. For instance, in June 2020, Philips and The University of Texas MD Anderson Cancer Center collaborated to facilitate personalized oncology treatments and clinical trials matching based on genomic markers.

SEGMENTATION

By Drug Class Analysis

To know how our report can help streamline your business, Speak to Analyst

Prophylaxis Segment Held the Highest Market Share in 2019

Based on drug class, the market is categorized into alkylating drugs, cytotoxic antibodies, antimetabolites, plant alkaloids, and others. The antimetabolites segment dominated the market in 2019. Antimetabolites are one of the most prescribed cytotoxic drugs for oncology and rheumatoid diseases. The higher adoption of this drug class is estimated to propel the segment growth in the coming years.

On the other hand, plant alkaloids hold the second-largest share in the global market. More than 95% of the plant alkaloids are administered through the infusion of IV. These factors are projected to drive the segment growth during the study period.

By Application Analysis

The market has been categorized into oncology, multiple sclerosis, rheumatoid arthritis, and others based on application. Among the applications, the oncology segment dominated the global market. The segment’s growth is driven by the ever-rising prevalence of cancer and the use of oncology drugs to treat the disease indication. Combined with this, high dependency on cytotoxic drugs to treat cancer is also a predominant factor influencing the growth of the segment in the forthcoming years.

By End-user Analysis

Hospital Pharmacy Segment Dominated the Market in 2019

Based on end-users, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Among the end-users, the hospital pharmacy segment dominated the global market. The segment's growth is influenced by the factor that the majority of the injectable cytotoxic drugs require administration of the molecule by a healthcare professional. Hence, the segment is also estimated to have the highest CAGR in the coming years.

REGIONAL INSIGHTS

To get more information on the regional analysis of this market, Request a Free sample

The market size in North America stood at USD 7.69 billion in 2019 and will grow considerably during the forecast period. The growth is attributable to the higher number of cancer patients and more extensive access to cancer drugs. For Instance, according to the American Cancer Society, in 2019, an estimated 268,600 new cases of invasive breast cancer were diagnosed in women, and about 2,670 cases were diagnosed in men in the U.S alone.

The growth of the market in Europe is attributable to various factors such as high healthcare expenditure on cancer and rheumatoid arthritis, favorable reimbursement policies, and active government initiatives to increase the accessibility of chemotherapy drugs, among others. According to the article published in the European Journal of Cancer, the European countries spent about US$ 243.6 Bn for cancer in 2018. Such increasing expenditures will propel the market growth in the region.

On the other hand, the Asia Pacific market is anticipated to showcase significant growth during the forecast duration. Factors, such as an increasing patient pool and expanding healthcare spending in the region, are supplementing the market growth in Asia Pacific. Moreover, the growing purchasing power of the masses in the emerging economies, namely, India and China, provides a huge opportunity for the market's growth.

Considerable growth in the injectable cytotoxic drugs market is anticipated during the forecast years in Latin America, and the Middle East and Africa. Countries in the region, including Latin America, and the Middle East and Africa are witnessing an increase in the demand for cancer, multiple sclerosis, and rheumatoid arthritis treatment options to cope up with the exponentially increasing patient population suffering from such diseases.

KEY INDUSTRY PLAYERS

Key Companies to Focus on Launching Cost-effective Treatment Options

The global market is fragmented and highly competitive with local as well as international players operating in the market. The market was dominated by Johnson and Johnson Services, Inc., garnering a majority share in 2019.  The company’s high focus on mergers and acquisitions to diversify its product portfolio is a predominant reason for its dominance in the market. Moreover, regular product approvals and the entrance of medium-sized companies are anticipated to increase the competition between the players. For instance, in December 2020, MacroGenics, Inc. received U.S FDA approval for its product MARGENZA to treat adult patients with metastatic HER2-positive breast cancer. Other players operating in the market include Sanofi, Eli Lily, and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer, Inc., among others. These players also play a key role in the pharmaceutical industry.

LIST OF KEY COMPANIES PROFILED:

• Johnson and Johnson Services Inc., (U.S)


• Sanofi (France)


• Eli Lilly and Company (U.S)


• Bristol-Myers Squibb Company (New York, U.S)


• F. Hoffmann-La Roche Ltd. (Basel, Switzerland)


• Novartis AG (Basel, Switzerland)


• Pfizer, Inc (New York, U.S)


• Merck & Co. Inc (New Jersey, U.S)


• Amgen (California, U.S.)

KEY INDUSTRY DEVELOPMENTS:

• May 2021 - Innovent Biologics, Inc. and Eli Lily and Company together announced that the U.S. FDA has approved their Biologics License Application for their investigational sintilimab injection in combination with pemetrexed and platinum chemotherapy for the treatment of patients with nonsquamous non-small cell lung cancer.


• June 2020 - F. Hoffmann-La Roche Ltd announced that they have received approval from the U.S. FDA for their investigational drug Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for the treatment of patients with HER2-positive breast cancer.


• May 2021 - Bristol Myers Squibb announced that the company received approval for Opdivo (nivolumab injection for intravenous use). The drug is approved for adjuvant treatment of patients who have went through neoadjuvant chemotherapy and are suffering from completely resected esophageal and gastroesophageal junction cancer with residual pathogenic disease.

REPORT COVERAGE

An Infographic Representation of Injectable Cytotoxic Drugs Market

View Full Infographic

To get information on various segments, share your queries with us

The injectable cytotoxic drugs market report provides qualitative and quantitative insights on the injectable cytotoxic drugs industry and a detailed analysis of market size and growth rate for all possible segments in the market. Along with this, the report provides an elaborative analysis of the market dynamics and competitive landscape. Various key insights are the prevalence of cancer by key regions, key industry developments, an overview of regulatory scenarios, pipeline analysis, and analysis of COVID-19 on the global market, among others.

Report Scope & Segmentation